Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2023-03-31 AGM Information
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Kallelse till årsstämma i Medivir AB (publ)
AGM Information Classification · 100% confidence The document is titled "Kallelse till årsstämma i Medivir AB (publ)" which translates to "Notice of Annual General Meeting in Medivir AB (publ)". The text details the date, time, location, procedures for participation (in person or by advance voting), agenda items (including election of board members, auditor, and proposals for changes to the articles of association), and voting rights. This content is characteristic of a formal notice convening a shareholders' meeting, specifically an Annual General Meeting (AGM). Therefore, the correct classification is AGM Information (AGM-R). The document length is substantial (over 44k characters), indicating it is the full notice/material, not just a brief announcement of the meeting.
2023-03-31 Swedish
Medivir har fastställt den rekommenderade fas 2-dosen för fostrox i kombination med Lenvima vid HCC
Regulatory Filings Classification · 85% confidence The document is a press release from Medivir AB announcing the successful completion of the initial dose-escalation part (Phase 1b) of a clinical study for their drug candidate fostrox in combination with Lenvima for HCC. It details the establishment of the recommended Phase 2 dose (RP2D) and provides context on the ongoing trial phases (1b/2a) and the medical need. This type of announcement, detailing clinical trial progress, safety profiles, and dose selection, is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses specifically on clinical trial results and dose selection rather than comprehensive quarterly financials (which would suggest IR) or a general regulatory filing (RNS), it fits best as an Earnings Release (ER) which often includes operational highlights, or potentially an Investor Presentation (IP) if it were structured as slides, but as a text announcement, ER is the closest fit for key operational/clinical updates. However, given the specific definitions, this is a clinical trial update announcing a key milestone (RP2D determination) and preliminary results. This is a significant operational update, often bundled with earnings, but it is not a formal Earnings Release (ER) which typically focuses on revenue/profit figures. It is also not a formal Investor Presentation (IP) which is usually a slide deck. It is a specific announcement about a drug development milestone. Since there is no specific category for 'Clinical Trial Update', we must choose the best fit. It is a detailed operational update, which often accompanies ERs, but it is not the ER itself. It is not a general regulatory filing (RNS) because it is highly specific. Given the content focuses on operational progress and results, ER is the most appropriate category among the choices for a major operational announcement, even if financial figures are absent. Alternatively, it could be classified as RNS if it's considered a general regulatory disclosure not covered elsewhere, but ER captures the nature of reporting clinical progress better than RNS. Revisiting the definitions: ER is 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is not financial results. IP is 'Detailed presentation for investors focusing on financials, strategy, and market position'. This is a press release, not a presentation. Given the lack of a specific clinical trial update category, and its nature as a significant corporate announcement, RNS (Regulatory Filings / fallback) is the safest general classification for a non-standard, non-financial, non-governance specific release. However, in many databases, significant clinical trial updates are often grouped with ERs or IRs. Since it's not a comprehensive report (IR) and not primarily financial (ER), RNS is the most accurate fallback for a specific corporate disclosure.
2023-02-20 Swedish
Medivir has determined the recommended phase 2 dose for fostrox in combination with Lenvima in HCC
Regulatory Filings Classification · 95% confidence The document is a press release from Medivir AB announcing the successful completion of the dose escalation part (phase 1b) of a clinical study for their drug fostrox in combination with Lenvima for Hepatocellular Carcinoma (HCC). It details the determination of the recommended phase 2 dose (RP2D) and provides context on the ongoing study, future plans (phase 2a), and background on the disease and the company. This type of announcement, focusing on clinical trial progress and preliminary results, is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is a specific, time-sensitive update on clinical progress rather than a comprehensive quarterly financial report (IR) or a general regulatory filing (RNS), and it contains key highlights (dose determined, positive safety profile), it aligns best with the 'Earnings Release' (ER) category, which often includes operational and clinical milestones alongside financial highlights, or it could be classified as a general Regulatory Filing (RNS) if it doesn't strictly fit ER. Given the focus on clinical trial milestones and the structure of a press release, ER is a strong candidate, but since it is not explicitly reporting quarterly financials, RNS (Regulatory Filings) serves as a safe and accurate fallback for specific operational updates that aren't explicitly defined elsewhere. However, many clinical trial updates are treated as ERs or IRs. Since it is not a comprehensive Interim Report (IR) and is a specific announcement, I will classify it as a Regulatory Filing (RNS) as it is a general announcement of material information, which is the fallback category for specific operational news not covered by other codes.
2023-02-20 English
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is a 'Bokslutskommuniké' (Year-end report) for Medivir AB covering the period January to December 2022. It contains comprehensive financial summaries, including income statements, cash flow, and balance sheet data for both the quarter and the full year, alongside detailed management commentary on clinical trials and business strategy. As it provides substantive financial statements and analysis for a period shorter than a full fiscal year (or in this case, the year-end preliminary report), it falls under the category of Interim/Quarterly Reports. FY 2022
2023-02-15 Swedish
Audit Report / Information 2022
Audit Report / Information Classification · 98% confidence The document is explicitly titled "MEDIVIR AB – YEAR-END REPORT JANUARY – DECEMBER 2022". It contains detailed financial summaries for the quarter (October-December) and the full year (January-December), including turnover, EBITDA, earnings per share, and cash flow. It also includes a CEO's message and detailed project updates. This structure is characteristic of a comprehensive annual financial report, which aligns with the definition of a 10-K (Annual Report), even though the specific SEC filing code '10-K' is not present, the content is clearly an annual report. It is not an Earnings Release (ER) because it is a comprehensive year-end report, not just an initial announcement of highlights. It is too detailed to be an Interim Report (IR) as it covers the full fiscal year. It is not a Report Publication Announcement (RPA) because it contains the full content, not just a notice of publication. FY 2022
2023-02-15 English
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Medivir AB covering the period January to September 2022. It contains detailed financial summaries, management commentary, and updates on clinical projects. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-11-03 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.